Experimental Hematology
Volume 38, Issue 7 , Pages 574-580, July 2010

Bone marrow stem cells and liver regeneration

Department of Animal Biotechnology, University of Nevada, Reno, Reno, Nev., USA

Received 7 April 2010; received in revised form 7 April 2010; accepted 13 April 2010. published online 26 April 2010.

Article Outline

Development of new approaches to treat patients with hepatic diseases that can eliminate the need for liver transplantation is imperative. Use of cell therapy as a means of repopulating the liver has several advantages over whole-organ transplantation because it would be less invasive, less immunogenic, and would allow the use, in some instances, of autologous-derived cells. Stem/progenitor cells that would be ideal for liver repopulation would need to have characteristics such as availability and ease of isolation, the ability to be expanded in vitro, ensuring adequate numbers of cells, susceptibility to modification by viral vector transduction/genetic recombination, to correct any underlying genetic defects, and the ability of restoring liver function following transplantation. Bone marrow−derived stem cells, such as hematopoietic, mesenchymal and endothelial progenitor cells possess some or most of these characteristics, making them ideal candidates for liver regenerative therapies. Here, we will summarize the ability of each of these stem cell populations to give rise to functional hepatic elements that could mediate repair in patients with liver damage/disease.

 

Liver failure is a potentially life-threatening condition for which organ transplantation is the only definitive therapy [1]. However, the current shortage of available livers for transplantation results in the deaths of many patients while awaiting transplantation [2]. Thus, it is imperative that new approaches for repairing the liver are developed, so that the need for transplanting a partial or complete human liver to cure the patient can be eliminated. Presently, cell therapies represent one of the most promising alternative solutions to entire or partial liver transplantation 3, 4, 5, 6, 7, 8, 9, 10, 11, 12. A logical alternative to performing liver transplantation would be to isolate and transplant human hepatocytes. Unfortunately, human livers would still be required as a source of cells and, in addition, isolation of human hepatocytes is difficult and inefficient. Furthermore, differentiated hepatocytes cannot be effectively expanded in culture, greatly limiting the number of hepatocytes that could be obtained from each liver 13, 14. Therefore, numerous studies have concentrated on investigating the ability of a variety of stem cells that can be readily isolated using noninvasive procedures, to give rise to hepatocytes both in vitro and in vivo. In addition, many of these cell populations can be expanded significantly in vitro, making it possible to generate large numbers of cells for transplantation from a fairly small number of initial stem cells. Because some of these stem cell populations are present within the adult, and could thus be isolated from the patient to be treated, it would be possible to produce personalized, immunologically matched hepatocytes.

Here we will discuss bone marrow (BM) as a source of some of the most promising stem cell candidates for liver regeneration/repair (Figure 1). We will present data supporting the ability of each of the stem cell populations to give rise to functional hepatic elements that could mediate repair in patients with liver damage/disease, and a summary of clinical trials using cell therapy for liver regeneration.

Back to Article Outline

Hematopoietic stem cells for liver regeneration 

Hematopoietic stem cells (HSC) are probably the most-studied and best-understood stem cell within the body [15]. Since pioneering studies in the early 1960s demonstrating that HSC existed within the marrow and were able to completely repopulate the hematopoietic system of lethally irradiated murine recipients 16, 17, 18, HSC have been the center of intensive research. HSC have been proven to be invaluable in the clinic, in the treatment of numerous hematologic and nonhematologic malignancies as well as a range of both inherited and acquired diseases. In addition to the BM, HSC can also be harvested from cytokine-mobilized peripheral blood and umbilical cord blood, making it possible to harvest these cells from the patient in adequate amounts, using relatively noninvasive procedures. Therefore, HSC meet the requirements of cells that would be ideally suited for cells therapies, such as availability, ease of isolation, and the ability to be harvested from the patient to be treated.

In the field of liver regeneration, HSC have received a great deal of attention as a result of ground-breaking studies showing that HSC, following transplantation, had the ability to give rise to hepatocyte-like cells in vivo and completely repopulate the liver of FAH mice, correcting their disease phenotype 19, 20. These studies were followed by others using a variety of rodent model systems to rigorously test the hepatocytic potential of HSC from various sources 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37. Table 1 shows the sources of cells used in studies that demonstrated the hepatocytic potential of enriched populations of HSC in various murine models with a wide range of genetic lesions and injuries induced by either chemicals or physical means. Because each group used different criteria for isolating HSC, and each injury/disease model seems to have its own unique characteristics, resulting in differing outcomes, the results from these studies have been rather hard to interpret, even when the same or very similar types of HSC are transplanted. However, it is safe to say that umbilical cord blood HSC appear to more consistently generate higher levels of hepatocytes following transplantation than HSC isolated from BM or mobilized peripheral blood. Furthermore, it is clear from these studies that HSC give rise to higher levels of liver engraftment when they are transplanted into models in which the host's endogenous hepatocytes are defective either as a result of genetic lesion or due to treatment with agents that prevent host hepatocyte replication. It appears that the only way to achieve high levels of donor HSC-derived hepatocytes is to somehow impart a proliferative/survival advantage to the transplanted cells. The mechanism whereby the hepatocytes are generated from the transplanted HSC has also been a controversial point among research groups. In some cases, such as the FAH model, it appears that the donor-derived hepatocytes are generated almost entirely through fusion of the transplanted HSC with the host's endogenous hepatocytes 20, 35, 38. However, in other models, the hepatocytes are generated almost exclusively through what seems to be true differentiation of the HSC into hepatocytes without exchange of any genetic or cellular elements between the host and the engrafted human cells 21, 25, 34, 36, 39. It has also been shown that the phenotype and purity of the cell population transplanted also influences the production of hepatocytes and whether fusion was observed or not 8, 9, 40, 41. Therefore, depending on the source of cells and etiology of disease, the outcome will differ significantly in terms of numbers and how hepatocytes are being generated. Using a noninjury model of transplantation in which the procedure is performed during the fetal period, when the liver is rapidly proliferating and differentiating, it is possible to obtain high levels of engraftment and differentiation of the donor human cells without forcing the transplanted cells to adopt a specific fate by damaging/inducing regeneration within the recipient liver 42, 43, 44, 45. The lack of injury is therefore important, because in the presence of disease/damage, the host hepatic microenvironment may be far more conducive to apoptosis than engraftment and differentiation [42], making it very hard to assess the true potential/ability of the transplanted cells 43, 44, 45, 46, 47, 48. Using the fetal sheep model, we performed a detailed head-to-head comparison between HSC from BM versus those of cord blood, and those from mobilized peripheral blood [49] with respect to their ability to give rise to functional hepatocytes in vivo. Our results showed that phenotypically identical HSC from three different clinically relevant sources possess marked differences in their hepatocytic potential, with cord blood HSC giving rise to the greatest numbers of hepatocytes, followed closely by BM−derived HSC, all in the absence of fusion. Of particular note, HSC derived from mobilized peripheral blood exhibited substantially lower hepatocytic potential than those from either cord blood or marrow, suggesting that mobilized peripheral blood will not likely prove to be the ideal source of HSC for hepatic repair/regeneration. We also compared the hepatocytic potentials among different putative HSC phenotypes and found that adult human BM CD34+Lin−CD38− cells were able to generate more hepatocytes in vivo than any other phenotype tested, suggesting that this fraction of cells are enriched not only for HSCs, but also for cells with hepatocytic potential [49]. In addition, our studies demonstrated that for each given HSC population, the hepatocytes generated from the hematopoietic graft expanded over time, gradually comprising a larger percentage of the total hepatic mass.

Table 1. Studies demonstrating hematopoietic stem cells hepatocytic potential in rodent models
Type of hematopoietic stem cellsFirst author, year
Adult mouse BM KTLSLagasse, 2000 [19]
Adult male mouse whole BMTheise, 2000 [37]
Adult male mouse BM HSC purified by elutriation, Lin−Krause, 2001[23]
Adult male Lin− BM cells from L-PK-Bcl-2 transgenic miceMallet, 2002 [24]
Adult mouse whole BMWang, 2002 [30]
Human cord blood CD34+ or CD45+Ishikawa, 2003 [34]
Human cord blood or mPB CD34+Kollet, 2003 [22]
Human cord blood mononuclear cellsNewsome, 2003 [25]
Male mouse Lin− BM cellsVassilopoulos, 2003 [20]
Human cord blood or BM CD34+ or CD34+CD38−CD7−Wang, 2003 [29]
Mouse BM cellsWang, 2003 [35]
Adult male mouse BM HSC purified by elutriation, Lin−Jang, 2004 [21]
Human cord blood mononuclear cells or eGFP transgenic mouse BM cellsSharma, 2005 [27]
Male GFP transgenic rat b2microglobulin(-) Thy-1(+) BM cellsMuraca, 2007 [36]
T-depleted mouse BM cellsEggenhofer, 2008 [31]

BM = bone marrow; eGFP = enhanced green fluorescent protein; GFP = green fluorescent protein; HSC = hematopoietic stem cell; mPB = mobilized peripheral blood; KTLS, Kit(+) Thy(low) Lin(−) Sca-1(+).

Back to Article Outline

Mesenchymal stem cells for liver regeneration 

Mesenchymal stem cells (MSC) make up part of the BM stromal microenvironment that provides support to the hematopoietic stem cell and drives the process of hematopoiesis 50, 51. Despite their important role within the BM, MSC are rare cells with estimates for MSC frequency ranging from 0.001% to 0.01% of the total nucleated cell population present within the marrow [52]. Like HSC, MSC cannot be isolated to absolute purity, although numerous culture methods and surface markers have been characterized that enable one to enrich for MSC, with each laboratory preferring its own method of isolation. This makes the comparison of results obtained by various laboratories very difficult, since each laboratory is likely studying somewhat different cell populations, despite the fact that all of these cells have collectively been referred to as MSC. In addition to the BM, these cells have now been isolated from numerous tissues, including brain, liver, lung, fetal blood, umbilical cord blood, kidney, and even liposuction material 53, 54, 55, 56, 57, 58, 59, leading one to postulate that MSC are likely to play a critical role in organ homeostasis, perhaps providing supportive factors, such as in the BM, and/or mediating maintenance/repair within their respective tissue.

Recent studies have shown that MSC, like HSC, have far greater differentiative abilities than previously thought. They, in fact, appear to be capable of giving rise to cells of all three germinal layers [60], including albumin-producing hepatocyte-like cells in vitro and in vivo 61, 62, 63, 64. However, in contrast to HSC, MSC can be expanded in culture for long periods of time without any seeming loss of differentiation capacity. Furthermore, because MSC are quite amenable to genetic modification/correction, MSC could be harvested from the patient's own marrow, even if the liver disease present was the result of an underlying genetic defect, and genetically corrected autologous MSC could thus be propagated to generate sufficient numbers of cells to achieve meaningful levels of engraftment following transplantation. Similar to the studies performed with human HSC, each group of investigators using MSC defined these cells in different ways, ranging from specific-antigen profile to simple plastic adherence, generating data that were not always in agreement. However, it is recognized overall that MSC appear to be able to exert beneficial effects in a wide range of injuries and disease states within the liver, and that fusion does not appear to play a major role in the beneficial effects of transplanted MSC. One issue that has complicated interpretation of the data generated from these studies in liver is that it appears that the transplantation of MSC somehow stimulates the host's liver to repair itself without the donor cells actually having to persist long-term within the recipient. Several studies clearly demonstrated that secretion of factors that stimulate regeneration of endogenous parenchymal cells were likely to play important roles in promoting tissue recovery 42, 65, 66, 67, 68, 69. These findings led to the question of whether MSC can actually generate hepatocytes or if, perhaps, all the effects they produce are simply mediated through release of soluble factors. In vitro studies have now provided definitive evidence that MSC can, under appropriate conditions be made to differentiate into cells with all of the characteristics of functional hepatocytes that can currently be assessed in culture 70, 71, 72, 73. Furthermore, MSC possess other equally important therapeutic effects besides contribution to the cellular pool. A variety of evidence from animal studies has now indicated that MSC have the ability to enhance fibrous matrix degradation, likely through induction of metalloproteinases, suggesting that MSC may be ideally suited for treatment of liver diseases involving fibrosis 3, 74, 75, 76, 77, 78, 79, 80. However, these results must be interpreted carefully because other studies have suggested that, under different conditions, transplanted MSC may actually contribute to the myofibroblast pool and thus enhance the fibrotic process within the liver 3, 81, 82, 83, 84. To rigorously test whether these qualities could be exploited to generate significant numbers of hepatocytes in vivo, we examined the ability of clonally derived human MSC from adult BM to generate functional albumin-producing hepatocytes in vivo following transplantation into fetal sheep recipients, comparing two routes of administration, intraperitoneal and intrahepatic [61]. Our results showed that, although MSC efficiently generated significant numbers of hepatocytes by both routes of administration, the intrahepatic injection resulted in substantially more efficient generation of hepatocytes. In addition to higher levels of hepatocytes, the animals that received an intrahepatic injection also exhibited a widespread distribution of hepatocytes throughout the liver parenchyma, while those receiving an intraperitoneal injection exhibited a preferential periportal distribution of human hepatocytes that produced higher amounts of albumin [61]. These studies thus provided compelling evidence that MSC represent a valuable source of cells for liver repair and regeneration and demonstrate that, by altering the site of injection, generation of hepatocytes occurs in different hepatic zones. In other studies, we evaluated the ability of mesenchymal cells derived from nonhematopoietic organs to form hepatic cells in vitro and in vivo [53]. After culture in specific inducing media, cells with hepatocyte-like morphology and phenotype were obtained, suggesting that metanephric-derived MSC could also serve as a source of cells with hepatic repopulating ability. Also, like their BM counterparts, these cells gave rise to significant numbers of human albumin-producing hepatocyte-like cells upon in utero transplantation. Similar results were also obtained using a novel adherent MSC-like cell population isolated from umbilical cord blood, which the authors termed unrestricted somatic stem cells [85]. This cord blood−derived MSC population was capable of giving rise to albumin-producing human parenchymal hepatic cells at levels of >20% in the recipient liver, in the absence of any injury or genetic defect. Another key aspect to assessing the utility of stem cell therapy for regenerative medicine for the liver, and for other organs as well, is the mechanism whereby the transplanted cells replace/repopulate the recipient liver [61]. We showed that MSC could give rise directly to cells within the liver without the need for first forming hematopoietic elements [86]. In more recent studies, we have now shown that the ability to directly contribute to liver repopulation without the need for a hematopoietic intermediate enables the transplanted MSC to rapidly begin contributing to the growing liver, producing cells with hepatic markers within as little as 24 or 48 hours post-transplantation [86]. The findings of these more recent studies confirmed our prior findings regarding the lack of a need for fusion, and furthered our understanding of the mechanism of hepatic repopulation by demonstrating that the generation of hepatocytes occurs independently of the transfer of either mitochondria or membrane-derived vesicles between the transplanted donor cells and the cells of the recipient liver [86]. These findings thus provide strong evidence to support genetic reprogramming and differentiation of the transplanted stem cells. The lack of fusion as a requirement for liver repopulation was in contrast to the results of numerous other studies employing injury models, raising the possibility that the efficacy and mechanism of stem cell repair will likely depend upon not only the stem cell population being transplanted, but also the nature of the injury/defect within the liver, and therefore the conditions within the hepatic microenvironment at the time of stem cell transplantation.

Back to Article Outline

Endothelial progenitor cells for liver regeneration 

A population of cells that may prove valuable in the repair/regeneration of damaged/diseased liver through the promotion of supportive factors necessary to the host's endogenous hepatocyte repair mechanisms is the so-called endothelial progenitor cells (EPCs). These cells have now been shown to engraft within the injured liver and generate new blood vessels through secretion of numerous growth factors, such as hepatocyte growth factor and vascular endothelial growth factor that assist in the regenerative process 87, 88, 89, 90, 91. Therefore, EPC improved the survival of mice that were subjected to severe liver injury, probably through stimulating regeneration of the liver via its own endogenous cellular reserves [89]. Also, in a rat model of cirrhotic liver disease, transplanted EPC incorporated into the portal tracts and fibrous septa, significantly reducing liver fibrosis [87]. Furthermore, in similarity to some of the effects observed following transplantation with BM−derived MSC, livers of animals receiving EPC transplantation showed significantly increased levels of matrix metalloproteinase−2, −9, and −13, with a concomitant reduction in levels of tissue inhibitor of metalloproteinase-1. Likewise, in rats with chronic liver injury induced by intraperitoneal injection of dimethylnitrosamine, EPC stimulated liver repair and suppression of liver fibrogenesis [88]. Stimulation of this regenerative process allowed maintenance of normal liver function parameters, such as transaminase, total bilirubin, total protein, and albumin, despite the continued administration of dimethylnitrosamine [88]. Thus, while only a small number of studies have been performed to date investigating the potential of EPCs for liver regeneration/repair, these investigations have provided compelling evidence that EPC transplantation is effective both at preventing liver fibrosis and for promoting regeneration in chronically damaged livers in which fibrosis is already well-established. Therefore, EPCs may prove to be a crucial cell type for therapies for liver disorders in which the host's own hepatocytes do not possess a genetic defect, and are thus capable of responding with proliferation to the array of supportive factors released by the engrafted cells repopulating the damaged regions of the liver.

Back to Article Outline

BM-derived stem cells in clinical trials 

Clinical use of BM-derived cells for repair/regeneration within the liver is still in its infancy. The unwillingness to test these cells in human patients is mainly due to the uncertainty of the outcome, based on conflicting studies in animal models, and the possibility of cellular fusion as a repair mechanism that may lead to genetically unstable hepatocytes within the environment of a diseased liver [5]. Five clinical feasibility studies in which the number of patients in each case has been small and no control arm has been included, have been reported thus far. The first of these investigated the effect of infusing autologous BM-derived CD133+ in patients who were undergoing partial hepatectomy for liver cancer, to expand a remnant segment of liver [92]. The results of this study were promising, in that patients receiving the infusion of BM cells (which likely contained both HSC and EPC) exhibited 2.5-fold higher mean proliferation rates when compared with a group of three consecutive patients who did not receive BM cells. Infusion of autologous CD34+ cells via either the portal vein or the hepatic artery was also shown to transiently improve serum bilirubin and albumin for >60 days in five patients suffering from cirrhosis [93]. Furthermore, a long-term follow-up in these patients demonstrated that four of five patients maintained improved clinical parameters for roughly 12 months post-infusion [94]. Two other recent studies have tested the safety and efficacy of using both CD34+ BM-derived cells [95] and BM MSC [96] to treat patients with cirrhosis. The infusion of CD34+ cells via the hepatic artery resulted in hepatorenal syndrome and death of one patient, with the remaining three patients showing no evidence of significant clinical improvement. In contrast, infusion of BM-derived MSC via a peripheral vein was found to be well-tolerated and have a definite therapeutic effect for two of four patients in the trial [96]. In the one other study that has thus far been reported, nine patients with cirrhosis were treated by portal vein infusion of autologous whole, unselected BM cells. Twenty-four−week follow-up revealed some improvement in Child-Pugh score, albumin, and biopsy evidence of an increase in hepatocyte turnover.

Although these studies provide hope that BM-derived cells may prove to be a valuable resource for cell-based therapies for liver disease, the results must be interpreted with some caution, given the limited number of patients enrolled in each trial and the lack of appropriate controls. Furthermore, because autologous cells were used in these trials, there was no way for the investigators to assess the actual engraftment, persistence, or differentiative potential of the transplanted cells, leaving the mechanism responsible for the observed clinical improvements open to speculation.

Back to Article Outline

Summary 

The current shortage of donor organs available for transplantation and the severe morbidity and mortality associated with this procedure underscore the need for alternatives to liver transplantation. The ability to repair the liver by transplanting BM-derived cells such as HSC, MSC, or EPC, rather than the liver itself, has shown great promise in animal models. Unfortunately, the lack of standardization of protocols for isolating specific cell types and the use of a variety of injury/disease models has made the interpretation of these results rather difficult, and has left open questions regarding the mechanism(s) whereby these cells mediate their beneficial effects. The results with human clinical trials, although promising, are not yet definitive, but have certainly sustained a reserved optimism as to the role of cell therapies for treating liver diseases, once methodologies have become standardized and optimized.

Back to Article Outline

Acknowledgments 

This work was supported by National Institutes of Health (Bethesda, MD, USA) grants HL73737, HL97623, and HL52955.

Back to Article Outline

Conflict of Interest Disclosure 

No financial interest/relationships with financial interest relating to the topic of this article have been declared.

Back to Article Outline

References 

  1. Lee WM, Squires RH, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology. 2008;47:1401–1415
  2. Kim WR, Kremers WK. Benefits of “the benefit model” in liver transplantation. Hepatology. 2008;48:697–698
  3. Alison M, Islam S, Lim S. Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly. J Pathol. 2009;217:282–298
  4. Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis. 2006;29:431–435
  5. Enns GM, Millan MT. Cell-based therapies for metabolic liver disease. Mol Genet Metab. 2008;95:3–10
  6. Fausto N. Liver regeneration: from laboratory to clinic. Liver Transpl. 2001;7:835–844
  7. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology. 2004;39:1477–1487
  8. Kallis YN, Alison MR, Forbes SJ. Bone marrow stem cells and liver disease. Gut. 2007;56:716–724
  9. Lysy PA, Campard D, Smets F, Najimi M, Sokal EM. Stem cells for liver tissue repair: current knowledge and perspectives. World J Gastroenterol. 2008;14:864–875
  10. Oertel M, Shafritz DA. Stem cells, cell transplantation and liver repopulation. Biochim Biophys Acta. 2008;1782:61–74
  11. Strom SC, Chowdhury JR, Fox IJ. Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis. 1999;19:39–48
  12. Strom SC, Fisher RA, Rubinstein WS, et al. Transplantation of human hepatocytes. Transplant Proc. 1997;29:2103–2106
  13. Serralta A, Donato MT, Martinez A, et al. Influence of preservation solution on the isolation and culture of human hepatocytes from liver grafts. Cell Transplant. 2005;14:837–843
  14. Serralta A, Donato MT, Orbis F, Castell JV, Mir J, Gomez-Lechon MJ. Functionality of cultured human hepatocytes from elective samples, cadaveric grafts and hepatectomies. Toxicol In Vitro. 2003;17:769–774
  15. Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol. 2006;169:338–346
  16. McCulloch EA, Till JE. The sensitivity of cells from normal mouse bone marrow to gamma radiation in vitro and in vivo. Radiat Res. 1962;16:822–832
  17. Siminovitch L, McCulloch EA, Till JE. The distribution of colony-forming cells among spleen colonies. J Cell Physiol. 1963;62:327–336
  18. Till JE, Mc CE. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961;14:213–222
  19. Lagasse E, Connors H, Al-Dhalimy M, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000;6:1229–1234
  20. Vassilopoulos G, Wang PR, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. Nature. 2003;422:901–904
  21. Jang YY, Collector MI, Baylin SB, Diehl AM, Sharkis SJ. Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol. 2004;6:532–539
  22. Kollet O, Shivtiel S, Chen YQ, et al. HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest. 2003;112:160–169
  23. Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105:369–377
  24. Mallet VO, Mitchell C, Mezey E, et al. Bone marrow transplantation in mice leads to a minor population of hepatocytes that can be selectively amplified in vivo. Hepatology. 2002;35:799–804
  25. Newsome PN, Johannessen I, Boyle S, et al. Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of cellular fusion. Gastroenterology. 2003;124:1891–1900
  26. Popp FC, Piso P, Schlitt HJ, Dahlke MH. Therapeutic potential of bone marrow stem cells for liver diseases. Curr Stem Cell Res Ther. 2006;1:411–418
  27. Sharma AD, Cantz T, Richter R, et al. Human cord blood stem cells generate human cytokeratin 18-negative hepatocyte-like cells in injured mouse liver. Am J Pathol. 2005;167:555–564
  28. Theise ND, Krause DS. Bone marrow to liver: the blood of Prometheus. Semin Cell Dev Biol. 2002;13:411–417
  29. Wang X, Ge S, McNamara G, Hao QL, Crooks GM, Nolta JA. Albumin-expressing hepatocyte-like cells develop in the livers of immune-deficient mice that received transplants of highly purified human hematopoietic stem cells. Blood. 2003;101:4201–4208
  30. Wang X, Montini E, Al-Dhalimy M, Lagasse E, Finegold M, Grompe M. Kinetics of liver repopulation after bone marrow transplantation. Am J Pathol. 2002;161:565–574
  31. Eggenhofer E, Popp FC, Renner P, et al. Allogeneic bone marrow transplantation restores liver function in Fah-knockout mice. Exp Hematol. 2008;36:1507–1513
  32. Fox IJ, Strom SC. To be or not to be: generation of hepatocytes from cells outside the liver. Gastroenterology. 2008;134:878–881
  33. Theise ND, Krause DS, Sharkis S. Comment on “Little evidence for developmental plasticity of adult hematopoietic stem cells.”. Science. 2003;299:1317;Author reply 1317
  34. Ishikawa F, Drake CJ, Yang S, et al. Transplanted human cord blood cells give rise to hepatocytes in engrafted mice. Ann N Y Acad Sci. 2003;996:174–185
  35. Wang X, Willenbring H, Akkari Y, et al. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature. 2003;422:897–901
  36. Muraca M, Ferraresso C, Vilei MT, et al. Liver repopulation with bone marrow derived cells improves the metabolic disorder in the Gunn rat. Gut. 2007;56:1725–1735
  37. Theise ND, Badve S, Saxena R, et al. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology. 2000;31:235–240
  38. Quintana-Bustamante O, Alvarez-Barrientos A, Kofman AV, et al. Hematopoietic mobilization in mice increases the presence of bone marrow-derived hepatocytes via in vivo cell fusion. Hepatology. 2006;43:108–116
  39. Tang XP, Zhang M, Yang X, Chen LM, Zeng Y. Differentiation of human umbilical cord blood stem cells into hepatocytes in vivo and in vitro. World J Gastroenterol. 2006;12:4014–4019
  40. Camargo FD, Finegold M, Goodell MA. Hematopoietic myelomonocytic cells are the major source of hepatocyte fusion partners. J Clin Invest. 2004;113:1266–1270
  41. Willenbring H, Bailey AS, Foster M, et al. Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nat Med. 2004;10:744–748
  42. Kuo TK, Hung SP, Chuang CH, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008;134:2111–21212121 e2111−2113
  43. Almeida-Porada G, Porada C, Zanjani ED. Adult stem cell plasticity and methods of detection. Rev Clin Exp Hematol. 2001;5:26–41
  44. Almeida-Porada G, Porada C, Zanjani ED. Plasticity of human stem cells in the fetal sheep model of human stem cell transplantation. Int J Hematol. 2004;79:1–6
  45. Almeida-Porada G, Zanjani ED. A large animal noninjury model for study of human stem cell plasticity. Blood Cells Mol Dis. 2004;32:77–81
  46. Civin CI, Almeida-Porada G, Lee MJ, Olweus J, Terstappen LW, Zanjani ED. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood. 1996;88:4102–4109
  47. Porada GA, Porada C, Zanjani ED. The fetal sheep: a unique model system for assessing the full differentiative potential of human stem cells. Yonsei Med J. 2004;45(Suppl):7–14
  48. Zanjani ED, Almeida-Porada G, Flake AW. The human/sheep xenograft model: a large animal model of human hematopoiesis. Int J Hematol. 1996;63:179–192
  49. Almeida-Porada G, Porada CD, Chamberlain J, Torabi A, Zanjani ED. Formation of human hepatocytes by human hematopoietic stem cells in sheep. Blood. 2004;104:2582–2590
  50. Friedenstein A, Kuralesova AI. Osteogenic precursor cells of bone marrow in radiation chimeras. Transplantation. 1971;12:99–108
  51. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17:331–340
  52. Galotto M, Berisso G, Delfino L, et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol. 1999;27:1460–1466
  53. Almeida-Porada G, El Shabrawy D, Porada C, Zanjani ED. Differentiative potential of human metanephric mesenchymal cells. Exp Hematol. 2002;30:1454–1462
  54. De Ugarte DA, Morizono K, Elbarbary A, et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs. 2003;174:101–109
  55. Fan CG, Tang FW, Zhang QJ, et al. Characterization and neural differentiation of fetal lung mesenchymal stem cells. Cell Transplant. 2005;14:311–321
  56. Gotherstrom C, West A, Liden J, Uzunel M, Lahesmaa R, Le Blanc K. Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica. 2005;90:1017–1026
  57. in 't Anker PS, Noort WA, Scherjon SA, et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica. 2003;88:845–852
  58. Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol. 2002;30:896–904
  59. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004;103:1669–1675
  60. Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr Stem Cell Res Ther. 2006;1:365–369
  61. Chamberlain J, Yamagami T, Colletti E, et al. Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep. Hepatology. 2007;46:1935–1945
  62. Lee KD, Kuo TK, Whang-Peng J, et al. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology. 2004;40:1275–1284
  63. Sato Y, Araki H, Kato J, et al. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood. 2005;106:756–763
  64. Schwartz RE, Reyes M, Koodie L, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest. 2002;109:1291–1302
  65. Banas A, Teratani T, Yamamoto Y, et al. IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells. 2008;26:2705–2712
  66. Parekkadan B, van Poll D, Megeed Z, et al. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun. 2007;363:247–252
  67. Parekkadan B, van Poll D, Suganuma K, et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE. 2007;2:e941
  68. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98:1076–1084
  69. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol. 1996;166:585–592
  70. Aurich H, Sgodda M, Kaltwasser P, et al. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut. 2009;58:570–581
  71. Banas A, Teratani T, Yamamoto Y, et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology. 2007;46:219–228
  72. Pan RL, Chen Y, Xiang LX, Shao JZ, Dong XJ, Zhang GR. Fetal liver-conditioned medium induces hepatic specification from mouse bone marrow mesenchymal stromal cells: a novel strategy for hepatic transdifferentiation. Cytotherapy. 2008;10:668–675
  73. Stock P, Staege MS, Muller LP, et al. Hepatocytes derived from adult stem cells. Transplant Proc. 2008;40:620–623
  74. Abdel Aziz MT, Atta HM, Mahfouz S, et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem. 2007;40:893–899
  75. Fang B, Shi M, Liao L, Yang S, Liu Y, Zhao RC. Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation. 2004;78:83–88
  76. Zhao DC, Lei JX, Chen R, et al. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J Gastroenterol. 2005;11:3431–3440
  77. Li JT, Liao ZX, Ping J, Xu D, Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol. 2008;43:419–428
  78. Zhao ZH, Xin SJ, Zhao JM, et al. [Dynamic expression of matrix metalloproteinase-2, membrane type-matrix metalloproteinase-2 in experimental hepatic fibrosis and its reversal in rat]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2004;18:328–331
  79. Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology. 2004;40:1304–1311
  80. Higashiyama R, Inagaki Y, Hong YY, et al. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology. 2007;45:213–222
  81. Asawa S, Saito T, Satoh A, et al. Participation of bone marrow cells in biliary fibrosis after bile duct ligation. J Gastroenterol Hepatol. 2007;22:2001–2008
  82. Baba S, Fujii H, Hirose T, et al. Commitment of bone marrow cells to hepatic stellate cells in mouse. J Hepatol. 2004;40:255–260
  83. Kisseleva T, Uchinami H, Feirt N, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol. 2006;45:429–438
  84. Russo FP, Alison MR, Bigger BW, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology. 2006;130:1807–1821
  85. Kogler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med. 2004;200:123–135
  86. Colletti E, Airey JA, Liu W, Simmons PJ, Zanjani ED, Porada CD, et al. Generation of tissue-specific cells by MSC does not require fusion or donor to host mitochondrial/membrane transfer. Stem Cell Res. 2009;2:125–138
  87. Nakamura T, Torimura T, Sakamoto M, et al. Significance and therapeutic potential of endothelial progenitor cell transplantation in a cirrhotic liver rat model. Gastroenterology. 2007;133:91–107e1
  88. Ueno T, Nakamura T, Torimura T, Sata M. Angiogenic cell therapy for hepatic fibrosis. Med Mol Morphol. 2006;39:16–21
  89. Taniguchi E, Kin M, Torimura T, et al. Endothelial progenitor cell transplantation improves the survival following liver injury in mice. Gastroenterology. 2006;130:521–531
  90. Liu F, Fei R, Rao HY, Cong X, Ha MH, Wei L. [The effects of endothelial progenitor cell transplantation in carbon tetrachloride induced hepatic fibrosis rats]. Zhonghua Gan Zang Bing Za Zhi. 2007;15:589–592
  91. Beaudry P, Hida Y, Udagawa T, et al. Endothelial progenitor cells contribute to accelerated liver regeneration. J Pediatr Surg. 2007;42:1190–1198
  92. am Esch JS, Knoefel WT, Klein M, et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells. 2005;23:463–470
  93. Gordon MY, Levicar N, Pai M, et al. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells. 2006;24:1822–1830
  94. Levicar N, Pai M, Habib NA, et al. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. Cell Prolif. 2008;41(Suppl 1):115–125
  95. Mohamadnejad M, Namiri M, Bagheri M, et al. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol. 2007;13:3359–3363
  96. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007;10:459–466

PII: S0301-472X(10)00150-5

doi:10.1016/j.exphem.2010.04.007

Experimental Hematology
Volume 38, Issue 7 , Pages 574-580, July 2010

Article Tools

* Image Usage & Resolution